Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 8, 2005, Pages 972-979

  Slart, Riemer H J A ^a   Bax, Jeroen J ^b   De Boer, Jaep ^c   Willemsen, Antoon T M ^a   Mook, Piet H ^a   Oudkerk, Matthijs ^a   Van Der Wall, Ernst E ^b   Van Veldhuisen, Dirk J ^a   Jager, Pieter L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Diaconessenhuis Meppel ^*  (Netherlands)

Author keywords

Acipimox; DISA SPECT; FDG; Myocardial viability; PET

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; AMMONIA N 13; DIPYRIDAMOLE; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART STRESS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RASH; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HEART LEFT VENTRICLE FUNCTION; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STUNNED HEART MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; MALE; MIDDLE AGED; MYOCARDIAL STUNNING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 23944480960     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1785-0     Document Type: Article

References (37)

1. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
2. Baer FM, Voth E, Deutsch HJ, Schneider CA, Horst M, de Vivie ER, et al. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60-9.
3. Bax JJ, Cornel JH, Visser FC, Fioretti PM, Van Lingen A, Reijs AE, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996;28:558-64.
4. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
5. Tamaki N, Kawamoto M, Tadamura E, Magata Y, Yonekura Y, Nohara R, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995;91:1697-705.
6. Delbeke D, Videlefsky S, Patton JA, Campbell MG, Martin WH, Ohana I, et al. Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med 1995;36:2110-9.
7. 99mTc-tetrofosmin-FDG collimated SPECT. J Nucl Med 2000;41:1318-23.
8. Sandler MP, Videlefsky S, Delbeke D, Patton JA, Meyerowitz C, Martin WH, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870-8.
9. 99mTc- sestamibi on dual-isotope simultaneous acquisition SPET compared with PET. Eur J Nucl Med Mol Imaging 2002;29:1357-64.
10. Bax JJ, Visser FC, Poldermans D, Van Lingen A, Elhendy A, Boersma E, et al. Safety and feasibility of cardiac FDG SPECT following oral administration of Acipimox, a nicotinic acid derivative: comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients. J Nucl Cardiol 2002;9:587-93.
11. Knuuti MJ, Yki-Jarvinen H, Voipio-Pulkki LM, Maki M, Ruotsalainen U, Harkonen R, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994;35:989-98.
12. 18F-FDG SPECT using acipimox for the assessment of myocardial viability. J Nucl Med 2003;44:877-83.
13. Schelbert HR, Beanlands R, Bengel F, Knuuti J, Dicarli M, Machac J, et al. PET myocardial perfusion and glucose metabolism imaging: part 2 - guidelines for interpretation and reporting. J Nucl Cardiol 2003;10:557-71.
14. 99mTc-sestamibi single photon emission computed tomography for the assessment of myocardial viability. Nucl Med Commun 2003;24:251-7.
15. Kool W, Willemsen ATM, Paans AMJ, Piers DA. Convolution based triple energy window crosstalk correction for DISA SPECT [abstract]. J Nucl Med 1997;38.
16. Hendel RC, Corbett JR, Cullom SJ, DePuey EG, Garcia EV, Bateman TM. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002;9:135-43.
17. Ficaro EP, Kritzman JN ,Corbett JR . Development and clinical validation of normal Tc-99m sestamibi database: comparison of 3D-MSPECT to Cequal [abstract]. J Nucl Med 1999;40 (suppl).
18. van der Geest RJ, Buller VG, Jansen E, Lamb HJ, Baur LH, van der Wall EE, et al. Comparison between manual and semi-automated analysis of left ventricular volume parameters from short-axis MR images. J Comput Assist Tomogr 1997;21:756-65.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
20. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York; 1981.
21. 18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998;97:843-50.
22. Camici PG, Wijns W, Borgers M, De Silva R, Ferrari R, Knuuti J, et al. Pathophysiological mechanisms of chronic reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997;96:3205-14.
23. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989;117:211-21.
24. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451-60.
25. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.
26. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997;30:1693-700.
27. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994;90:2687-94.
28. Canty J-MJ, Fallavollita JA. Resting myocardial flow in hibernating myocardium: validating animal models of human pathophysiology. Am J Physiol 1999;277:H417-22.
29. Vanoverschelde JL, Wijns W, Depre C, Essamri B, Heyndrickx GR, Borgers M, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-23.
30. Vanoverschelde JL, Melin JA. The pathophysiology of myocardial hibernation: current controversies and future directions. Prog Cardiovasc Dis 2001;43:387-98.
31. Rambaldi R, Poldermans D, Bax JJ, Boersma E, Valkema R, Elhendy A, et al. Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. Am J Cardiol 1999;84:130-4.
32. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352-60.
33. 99mTc-sestamibi myocardial perfusion scintigraphy: the impact of 1 year's experience. Eur J Nucl Med Mol Imaging 2003;30:1505-9.
34. Burt RW, Perkins OW, Oppenheim BE, Schauwecker DS, Stein L, Wellman HN, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176-9.
35. Martin WH, Delbeke D, Patton JA, Hendrix B, Weinfeld Z, Ohana I, et al. FDG-SPECT: correlation with FDG-PET. J Nucl Med 1995;36:988-95.
36. Bax JJ, Visser FC, Blanksma PK, Veening MA, Tan ES, Willemsen TM, et al. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med 1996;37:1631-6.
37. Chen EQ, MacIntyre WJ, Go RT, Brunken RC, Saha GB, Wong CY, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997;38:582-6.